Autophagy 2012-12-01

Deprive to kill: glutamine closes the gate to anticancer monocarboxylic drugs.

Simone Cardaci, Maria Rosa Ciriolo

Index: Autophagy 8(12) , 1830-2, (2012)

Full Text: HTML

Abstract

Killing properties of antitumor drugs can be enhanced by strategies targeting biochemical adaptations of cancer cells. Recently, we reported that depriving cancer cells of glutamine is a feasible approach to enhance antitumor effects of the alkylating analog of pyruvic acid, 3-bromopyruvate, which rely on the induction of autophagic cell death by metabolic-oxidative stress. 3-bromopyruvate chemopotentiation is the result of its increased intracellular uptake mediated by the monocarboxylate transporter 1, whose expression is post-transcriptionally increased upon glutamine withdrawal. Overall, our results identified the metabolic condition able to increase the selectivity of 3-bromopyruvate targets in neoplastic tissues, thereby providing a stage for its use in clinical settings for targeting malignancies and represent a proof of principle that modulation of glutamine availability can influence the delivery of monocarboxylic drugs into tumors.

Related Compounds

  • 3-Bromopyruvic aci...

Related Articles:

3-Bromopyruvate: A novel antifungal agent against the human pathogen Cryptococcus neoformans

2013-05-03

[Biochem. Biophys. Res. Commun. 434(2) , 322-7, (2013)]

Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.

2014-07-15

[Oncotarget 5(13) , 5177-89, (2014)]

Insights into the carboxyltransferase reaction of pyruvate carboxylase from the structures of bound product and intermediate analogs.

2013-11-01

[Biochem. Biophys. Res. Commun. 441(2) , 377-82, (2013)]

Regulation of the proliferation of colon cancer cells by compounds that affect glycolysis, including 3-bromopyruvate, 2-deoxyglucose and biguanides.

2013-02-01

[Anticancer Res. 33(2) , 401-7, (2013)]

3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue.

2012-02-01

[J. Bioenerg. Biomembr. 44(1) , 1-6, (2012)]

More Articles...